Gene-edited T cells for advanced breast or prostate cancer
Part of Cancer, Kidney & urinary, Skin clinical trials.
This trial tests a new therapy called CRG-150, which uses your own immune cells that have been gene-edited to fight cancer. It is for people with certain types of metastatic breast or prostate cancer who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have one of these cancers that has spread: HR+HER2- breast cancer, triple-negative breast cancer, or prostate cancer.
- You must have already tried at least two standard treatments for your metastatic cancer.
- You must be in reasonably good health, with a performance status of 0 or 1.
- You must have adequate organ function, including blood counts, kidney function, and heart function.
- You cannot be on high-dose steroids, have an active autoimmune disease, or have had a recent major surgery or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
This trial tests a new treatment called GC203 TIL, which uses your own immune cells (TILs) that have been gene-edited to fight pancreatic cancer. It is for people whose cancer has not responded to standard treatments and who are healthy enough to undergo this therapy.
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
This trial tests a new cell therapy called TRTs for people with advanced cancers like stomach, esophagus, cervical, breast, or lung cancer that no longer respond to standard treatments. The therapy uses your own tumor tissue or fluid to create a personalized treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.